Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Trial ID or NCT#
NCT05416554
Status
NOT RECRUITING
Purpose
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Official Title
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * \>/= 18 years-old* Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or* Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers* \>/= 6 months from the date of CAR-T infusion* Fluent in English* Able to attend and participate in in-person testing (Arm I)* Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
Exclusion Criteria:
- * Concurrent enrollment in a CAR-T therapeutics research study* Unable to be present for the scheduled testing* Unable to participate in testing due to severe cognitive or physical limitation* Actively receiving chemotherapy* Progressive cancer
Investigator(s)
Brian J Scott
Neurohospitalist
Clinical Professor, Neurology & Neurological Sciences
Clinical Associate Professor (By courtesy), Neurosurgery
Matthew Frank
Blood and marrow transplant specialist,
Hematologist-Oncologist
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Michelle Monje
Contact us to find out if this trial is right for you.
Contact
Brian J Scott, MD
bjscott@stanford.edu
View on ClinicalTrials.gov
